Institute of Diabetes and Obesity, Helmholtz Center Munich, Germany
Mini Review
The Atomic Pharmacology of Glucagon Agonists in Diabetes and Heftiness
Author(s): Timo Müller*
Glucagon agonists have emerged as promising therapeutic agents for the management of diabetes and obesity, offering a targeted approach to modulate key physiological pathways at the molecular level. This abstract provides a concise overview of the atomic pharmacology of glucagon agonists, highlighting their mechanisms of action and the implications for treating diabetes and obesity. Glucagon, traditionally recognized for its role in glucose homeostasis, has garnered attention as a potential target for therapeutic intervention in metabolic disorders. Agonists designed to mimic the actions of endogenous glucagon engage with specific receptors, initiating a cascade of molecular events that influence cellular function.
The atomic pharmacology of glucagon agonists involves binding to the glucagon receptor, a G protein-coupled receptor predominantly expressed in the liver, adipose.. View More»
DOI:
10.35248/2155-6156.10001052
